Celltrion aims for KRW 5T sales with 'ADC‧CDMO'
By Hwang, Byung-woo | translator Eo, Yun-Ho
24.09.12 05:17:11
가나다라
0
Announced a strategic plan for developing biosimilars and new drugs…will disclose new pipelines, such as ADC
Expected to generate a total of KRW 3.5 trillion in sales for 2024…aims for 5 trillion sales next year, based on Zymfentra sales
Celltrion will secure a manufacturing plant by incorporating wholly owned subsidiary
Celltrion aims to achieve KRW 5 trillion in sales by 2025 based on the growth of the biosimilar pipeline and new business operations.
▲Celltrip Group President Seo Jung-jin (center) and Celltrion CEO Seo Jin-seok (right).
Celltrip Group President Seo Jung-jin and Celltrion CEO Seo Jin-seok announced on September 9th that they have participated in the 'Morgan Stanley 22nd Annual Global Healthcare Conference' in the United States on September 6th and presented the group's strategic plan for the future.
Morgan Stanley Global Healthcare Conference is an event hosted by the global investment bank (IB) Morgan Stanley. It invites promising biotechnology companies worldwide and provides an opportunity to meet with global institutional investors. This year marks the 22nd eve
Hwang, Byung-woo(tuai@dailypharm.com)
If you want to see the full article, please JOIN US (click)